Tesamorelin Peptide: A Researcher’s Guide

Key takeaways

• Tesamorelin is GHRH with a trans-3-hexenoic acid group, all 44 amino acids of the human sequence.
• It signals the pituitary to release growth hormone rather than supplying growth hormone.
• Approved in 2010 for HIV-associated lipodystrophy, on the strength of trials in over 400 patients.
• The approval covers a regulated product. It says nothing about a research-grade vial.
• At 44 residues it is long by research-market standards, which makes the analytical method behind a purity figure matter more.

What is tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone releasing hormone. It contains all 44 amino acids of human GHRH with a trans-3-hexenoic acid group attached, which slows breakdown in plasma and gives the molecule a usable half-life.

The distinction that matters most: tesamorelin does not supply growth hormone. It signals the pituitary to release the body’s own, which is why its effect profile differs from injected growth hormone. It was developed by Theratechnologies in Canada under the code TH9507.

Chemically it is a large peptide by research-market standards. The molecular formula is C221H366N72O67S and the molecular weight is roughly 5,136 g/mol, several times the size of the short sequences that dominate vendor catalogues. Longer sequences are harder to synthesise cleanly, which is directly relevant to what a purity report on tesamorelin means.

What does the research on tesamorelin actually show?

Tesamorelin is the rare compound on this site with a completed Phase 3 programme and a regulatory approval behind it. It was approved in 2010 for the reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy, and the evidence for that indication is real.

The pivotal work randomised 404 patients on antiretroviral therapy with excess abdominal fat across 12 months, comparing tesamorelin at 2 mg by daily subcutaneous injection against placebo in a 2:1 ratio. A separate 26-week extension re-randomised patients to continue or switch, which is how the durability question was answered rather than assumed.

Study	Design	Participants	What it found
Phase 3, NCT00123253	Randomised, placebo-controlled, HIV-associated lipodystrophy	412	Basis of the 2010 approval for reducing excess visceral abdominal fat
Phase 3 extension, NCT00608023	Re-randomised continuation	263	Addressed whether the effect held beyond the initial period
12-month trial (PMID 20101189)	Randomised 2:1, tesamorelin 2 mg daily against placebo	404	Selective reduction of visceral adipose tissue
26-week extension (PMID 18690162)	273 on tesamorelin against 137 on placebo, then re-randomised	410	Long-term safety and glucose parameters assessed
NAFLD trial, NCT03375788	Completed, outside the approved indication	51	Studied hepatic fat rather than lipodystrophy

Work has since extended beyond the approved indication. A completed trial studied the same molecule in non-alcoholic fatty liver disease, and systematic reviews published in 2026 have revisited body composition and hepatic fat outcomes. That research is genuine, but it does not carry the same weight as the approval, and it does not describe every use the compound is marketed for. The same pattern shows up across the compound profiles on this site.

What does approval mean for a research-grade vial?

It means less than it appears. Every figure in the trial record came from a pharmaceutical product made to regulated manufacturing standards at a verified concentration. A vial labelled tesamorelin from a research supplier is a different object from a different production chain.

This is the same gap that applies across the research market, but it is wider here precisely because the approved product exists. The trial data are strong, which makes it tempting to read them as describing whatever arrives in the post. They do not. The trials describe the approved medicine. It is the same distinction we draw on the GLP-1 agonists page, where approved drugs and research-market copies get confused most often.

The practical consequence is that the approval tells you the molecule can do something under controlled conditions. It tells you nothing about identity, purity or concentration in a research vial. Only a third-party analysis of that specific batch does. See how third-party testing works for what such a report can and cannot establish.

What should a tesamorelin certificate of analysis show?

The same elements as any peptide report, with one addition that matters for a 44-residue sequence: the method has to be capable of separating closely related impurities, and the report should say which method was used rather than stating a bare percentage.

Long sequences accumulate truncation and deletion products during synthesis. A short peptide that fails to couple cleanly gives an obviously different mass; a 44-residue chain missing one residue is far closer to the target and harder to resolve. A purity figure produced without a named method is not verifiable, and on a molecule this size that gap is not academic.

Compare the batch number on the report against the number on the vial. A certificate that does not carry a matching lot number describes some batch, not necessarily yours. Which suppliers publish batch-matched reports is covered in our vendor assessments. The full checklist sits in our guide to reading a certificate of analysis.

Frequently asked questions

What is tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone releasing hormone, containing all 44 amino acids of human GHRH with a trans-3-hexenoic acid group attached. It signals the pituitary to release the body own growth hormone rather than supplying growth hormone directly.

Is tesamorelin approved?

Yes, which makes it unusual among compounds sold on the research market. It was approved in 2010 for reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy. Approval covers that indication and that manufactured product, not every use it is marketed for. That indication is also why tesamorelin heads our roundup of peptides for visceral fat loss.

Does the trial data apply to a research-grade vial?

No. Every trial figure came from a pharmaceutical product made to regulated standards at a verified concentration. A research vial comes from a different manufacturing chain. The trials describe the approved medicine, not the contents of that vial.

What dose was used in the trials?

The pivotal studies used 2 mg by daily subcutaneous injection. That figure describes the trial protocol under medical supervision and is reported here as a fact about the research record.

Why does sequence length matter for tesamorelin purity?

At 44 residues tesamorelin is several times longer than the short peptides that dominate vendor catalogues. Longer chains accumulate truncation and deletion products during synthesis, and a chain missing a single residue is close in mass to the target and harder to resolve. The analytical method used therefore matters more, not less.

What should a tesamorelin certificate of analysis include?

The testing laboratory and its contact details, a batch number matching the vial, the date of testing, the named method such as HPLC or mass spectrometry, and a numeric purity result rather than a pass or fail. A percentage with no method behind it cannot be verified.

Primary sources

• Falutz J et al. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation. J Acquir Immune Defic Syndr, 2010 (PMID 20101189)
• Long-term safety and effects of tesamorelin: 26-week extension. AIDS, 2008 (PMID 18690162)
• Tesamorelin: a review of its use in HIV-associated lipodystrophy. Drugs, 2011 (PMID 21668043)
• Efficacy and Safety of Tesamorelin in People Living With HIV With Lipodystrophy: A Systematic Review, 2026 (PMID 42538058)
• ClinicalTrials.gov NCT00123253: Phase 3 in HIV-associated lipodystrophy (completed)
• ClinicalTrials.gov NCT03375788: GHRH analogue in non-alcoholic fatty liver disease (completed)
• PubChem CID 16137828: Tesamorelin
• Tesamorelin on Wikipedia